376 related articles for article (PubMed ID: 9075665)
1. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.
Walsh KM; Timms P; Campbell S; MacSween RN; Morris AJ
Dig Dis Sci; 1999 Mar; 44(3):624-30. PubMed ID: 10080160
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
[TBL] [Abstract][Full Text] [Related]
4. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
5. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients.
Ninomiya T; Yoon S; Nagano H; Kumon Y; Seo Y; Kasuga M; Yano Y; Nakaji M; Hayashi Y
Intervirology; 2001; 44(4):227-31. PubMed ID: 11509885
[TBL] [Abstract][Full Text] [Related]
6. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
[TBL] [Abstract][Full Text] [Related]
7. Evidence for altered hepatic matrix degradation in genetic haemochromatosis.
George DK; Ramm GA; Powell LW; Fletcher LM; Walker NI; Cowley LL; Crawford DH
Gut; 1998 May; 42(5):715-20. PubMed ID: 9659170
[TBL] [Abstract][Full Text] [Related]
8. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation.
Manicourt DH; Fujimoto N; Obata K; Thonar EJ
Arthritis Rheum; 1995 Aug; 38(8):1031-9. PubMed ID: 7639798
[TBL] [Abstract][Full Text] [Related]
9. Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.
Latronico T; Mascia C; Pati I; Zuccala P; Mengoni F; Marocco R; Tieghi T; Belvisi V; Lichtner M; Vullo V; Mastroianni CM; Liuzzi GM
Int J Mol Sci; 2016 Mar; 17(4):455. PubMed ID: 27023536
[TBL] [Abstract][Full Text] [Related]
10. Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon.
Arai M; Niioka M; Maruyama K; Wada N; Fujimoto N; Nomiyama T; Tanaka S; Okazaki I
Dig Dis Sci; 1996 May; 41(5):995-1000. PubMed ID: 8625775
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.
Lichtinghagen R; Huegel O; Seifert T; Haberkorn CI; Michels D; Flemming P; Bahr M; Boeker KH
Clin Chem; 2000 Feb; 46(2):183-92. PubMed ID: 10657374
[TBL] [Abstract][Full Text] [Related]
12. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).
Magrin S; Craxi A; Fabiano C; Marino L; Fiorentino G; Lo Iacono O; Volpes R; Di Marco V; Almasio P; Vaccaro A; Urdea MS; Wilber JC; Bonura C; Gianguzza F; Capursi V; Filiberti S; Stuyver L; Pagliaro L
J Hepatol; 1996 Nov; 25(5):583-90. PubMed ID: 8938531
[TBL] [Abstract][Full Text] [Related]
13. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
[TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis.
Murawaki Y; Ikuta Y; Idobe Y; Kawasaki H
J Gastroenterol Hepatol; 1999 Feb; 14(2):138-45. PubMed ID: 10029294
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease.
Murawaki Y; Yamada S; Ikuta Y; Kawasaki H
J Hepatol; 1999 Jun; 30(6):1090-8. PubMed ID: 10406188
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta.
Tamarina NA; McMillan WD; Shively VP; Pearce WH
Surgery; 1997 Aug; 122(2):264-71; discussion 271-2. PubMed ID: 9288131
[TBL] [Abstract][Full Text] [Related]
17. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
Shindo M; Arai K; Okuno T
J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV.
Mastroianni CM; Liuzzi GM; D'Ettorre G; Lichtner M; Forcina G; Di Campli NF; Riccio P; Vullo V
HIV Clin Trials; 2002; 3(4):310-5. PubMed ID: 12187505
[TBL] [Abstract][Full Text] [Related]
19. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.
Kossakowska AE; Edwards DR; Lee SS; Urbanski LS; Stabbler AL; Zhang CL; Phillips BW; Zhang Y; Urbanski SJ
Am J Pathol; 1998 Dec; 153(6):1895-902. PubMed ID: 9846979
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
